Change in Metabolic Syndrome Parameters With Antipsychotic Treatment in the CATIE Schizophrenia Trial: Prospective Data From Phase 1

BACKGROUND: The metabolic syndrome (MS) is associated with increased risk for diabetes mellitus and coronary heart disease, and is highly prevalent among schizophrenia patients. Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Meyer, Jonathan M., Davis, Vicki G., Goff, Donald C., McEvoy, Joseph P., Nasrallah, Henry A., Davis, Sonia M., Rosenheck, Robert A., Daumit, Gail L., Hsiao, John, Swartz, Marvin S., Stroup, T. Scott, Lieberman, Jeffrey A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2008
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3673564/
https://ncbi.nlm.nih.gov/pubmed/18258416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.schres.2007.12.487
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia